Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
Xin Lu, [email protected] These authors have contributed equally to this work ORCID: Zixuan Hu, orcid.org/0009-0000-7508-5457
Flow Space spoke with Dr
To determine whether the observed improvements were independent of weight loss, variables showing significant changes in univariate analyses were further examined using a repeated-measures general linear model (GLM) with TIME (baseline vs
24, 25 In agreement with previous studies, 25 weight loss in all groups increased concentrations of adiponectin and reduced fibrinogen levels
Full disclaimer VENTURE Phase 2 Results: What the Data Shows Viking Therapeutics presented full data from the Phase 2 VENTURE-Oral Dosing trial at the European Congress on Obesity (ECO) in May 2026
